IDEXX LABORATORIES INC /DEIDXX
IDEXX LABORATORIES INC /DE Financial Overview 2021–2025
Updated Jul 10, 2026IDEXX Laboratories expanded its operating income by 20.5% to $1.36 billion in FY2025, proving the deep pricing power embedded in its veterinary diagnostics ecosystem. The core investment thesis relies on a sticky, recurring revenue model built around essential companion animal healthcare that heavily insulates the business from macroeconomic turbulence. Because advanced diagnostics and laboratory consumables are critical for daily veterinary clinic operations, IDEXX consistently passes along price increases to offset inflation while driving sustained profitability.
This predictable demand allowed total revenue to grow from $3.22 billion in FY2021 to $4.30 billion in FY2025. The Companion Animal Group anchors this trajectory, generating $3.95 billion in FY2025 as recurring diagnostic revenues regularly accounted for roughly 80% of the consolidated top line. These high-margin recurring streams fundamentally shifted the underlying profitability of the business, pushing the company's gross profit margin from 59.5% in FY2022 to 61.8% in FY2025. Management systematically directed the resulting cash flow toward shareholder returns, deploying $837.0 million for stock repurchases during FY2024 alone.
Investors have assigned a steep premium to this operational consistency. At the close of FY2025, the market rewarded IDEXX with a $53.9 billion market capitalization, and the stock traded at $676.53. This priced the company at a demanding 51.7x multiple against its $13.08 earnings per share for the year, reflecting high market confidence in its ongoing ability to extract highly predictable cash flows from the global pet healthcare sector.
Recent Developments (Q4 2025 and Q1 2026)
IDEXX Laboratories approaches a major leadership transition following robust Q1 2026 performance. Dr. Michael Erickson will succeed Jay Mazelsky as CEO on May 12, 2026, taking over an increasingly efficient operation. The company generated $1.14 billion in Q1 2026 revenue, representing a 14.3% year-over-year expansion. Strong pricing realization pushed the gross profit margin up 100 basis points to 63.4%. This operating leverage lifted quarterly net income by 14.8% to $278.4 million, yielding $3.47 per share. The company supplemented this internal growth by deploying $360.8 million for open-market share repurchases during the quarter.
Bulls argue the accelerating top-line growth and quarterly margin expansion demonstrate an unassailable moat in companion animal diagnostics. Bears caution that despite a share price pullback to $562.97, the stock remains richly valued at 43.0x earnings as of May 5, 2026, leaving zero room for execution missteps under new management.
What to watch: strategic direction and capital allocation under the incoming CEO; ongoing integration of artificial intelligence into reference laboratory services.
Rev
$4.30B
FY2025
NI
$1.06B
FY2025
EPS
$13.17
FY2025
OCF
$1.18B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
IDEXX LABORATORIES INC /DE 8-K Report, Bylaw Amendment (May 15, 2026)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on May 15, 2026, detailing significant corporate governance changes approved by shareholders at the May 12, 2026 annual meeting. The primary focus is the amendment to the Certificate of Incorporation and By-Laws to declassify the Board of Directors over a three-year period, with all directors to be elected annually starting in 2029. This move enhances shareholder oversight and aligns with modern corporate governance trends, making the board more directly accountable to shareholders. Furthermore, shareholders approved amendments granting a right to call a special meeting to those holding at least 25% of the company's capital stock continuously for at least one year. This provides a critical mechanism for shareholders to address urgent matters outside of the regular annual meeting schedule, increasing their influence and ability to effect change. The report also confirms the ratification of PricewaterhouseCoopers LLP as the independent auditor and the advisory approval of executive compensation, alongside the election of three Class II directors.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (May 5, 2026)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on May 5, 2026, to report its financial results for the quarter ended March 31, 2026. The filing primarily furnished a press release containing these results, which is attached as Exhibit 99.1. Investors should note that this information is being furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings, unless specifically stated. While the specific financial figures from the press release are not detailed within the 8-K text itself, this report serves as the official notification to the market of IDEXX's first-quarter performance. Investors seeking detailed insights into revenue, profitability, and any forward-looking statements will need to refer to the furnished press release (Exhibit 99.1).
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Mar 26, 2026)
IDEXX Laboratories, Inc. (IDXX) filed an 8-K on March 26, 2026, to report the departure of Dr. Nimrata Hunt, Executive Vice President of Global Strategy and Commercial, effective April 13, 2026. This departure was a mutual agreement, and Dr. Hunt will provide advisory services until July 13, 2026. The company has entered into a separation agreement that outlines the terms of her exit and advisory role. Investors should note the financial implications of Dr. Hunt's departure, including a separation package totaling approximately $2.24 million in salary continuation and target bonuses, along with COBRA premium costs, transition assistance, and tax/financial planning reimbursements. The company is classifying this as a termination without cause. The agreement also includes standard clauses like general release of claims, non-disparagement, and ongoing adherence to restrictive covenants. This filing primarily addresses a significant executive transition and associated costs.
IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Feb 13, 2026)
IDEXX Laboratories, Inc. (IDXX) announced a change in its Board of Directors composition. Ms. M. Anne Szostak has notified the company of her intention to retire from the Board, effective immediately after the 2026 Annual Meeting of Stockholders on May 12, 2026. Her retirement is not due to any disagreements concerning the company's operations or policies, indicating a smooth transition. The company expressed gratitude for her significant contributions and leadership since 2012. The Board will reduce the size of the Class III directors upon Ms. Szostak's retirement. This reduction, however, will be offset by the previously announced appointment of Michael G. Erickson, PhD, as a Class II director, also effective immediately following the 2026 Annual Meeting. Investors should note that these changes are procedural and do not appear to reflect any underlying issues with the company's performance or governance.
IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Feb 2, 2026)
IDEXX Laboratories, Inc. (IDXX) has filed a Current Report on Form 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report, filed on February 2, 2026, primarily serves to furnish the accompanying press release containing these financial details. Investors should note that the information provided in this filing is furnished under Item 2.02 and is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it automatically incorporated into other filings unless specifically referenced. The key takeaway for investors is the announcement of the company's performance for the recently concluded fiscal year and the final quarter. While the specific financial figures are contained within the furnished press release (Exhibit 99.1), this 8-K filing formally brings those results into the public domain. Investors interested in IDXX's operational and financial condition should refer to the press release for detailed metrics, revenue figures, profitability, and any forward-looking statements or guidance.
View all 8-K filings →